Stem definition | Drug id | CAS RN |
---|---|---|
beta-lactamase inhibitors | 669 | 58001-44-8 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 43 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 31.38 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 75 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.22 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.91 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 6, 1984 | FDA | DR REDDYS LABS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bronchiectasis | 114.93 | 21.02 | 41 | 4584 | 11393 | 56276049 |
Bone erosion | 104.16 | 21.02 | 41 | 4584 | 14933 | 56272509 |
Acute generalised exanthematous pustulosis | 75.63 | 21.02 | 29 | 4596 | 9840 | 56277602 |
Hypothyroidism | 72.87 | 21.02 | 43 | 4582 | 38153 | 56249289 |
Neutropenia | 57.86 | 21.02 | 68 | 4557 | 158099 | 56129343 |
Anaphylactic reaction | 55.87 | 21.02 | 43 | 4582 | 58952 | 56228490 |
Drug hypersensitivity | 53.29 | 21.02 | 87 | 4538 | 275118 | 56012324 |
Nail dystrophy | 48.49 | 21.02 | 12 | 4613 | 940 | 56286502 |
Axillary pain | 41.42 | 21.02 | 12 | 4613 | 1713 | 56285729 |
Loss of personal independence in daily activities | 40.17 | 21.02 | 41 | 4584 | 81328 | 56206114 |
Hepatitis cholestatic | 39.16 | 21.02 | 16 | 4609 | 6398 | 56281044 |
Cholecystitis chronic | 38.86 | 21.02 | 18 | 4607 | 9730 | 56277712 |
Appendicitis | 37.10 | 21.02 | 16 | 4609 | 7316 | 56280126 |
Jaundice | 35.19 | 21.02 | 24 | 4601 | 27270 | 56260172 |
Catheter site haemorrhage | 34.82 | 21.02 | 12 | 4613 | 3006 | 56284436 |
Pruritus | 33.96 | 21.02 | 78 | 4547 | 316545 | 55970897 |
Cholestasis | 30.80 | 21.02 | 22 | 4603 | 26891 | 56260551 |
Toxic skin eruption | 29.93 | 21.02 | 16 | 4609 | 11723 | 56275719 |
Hyperleukocytosis | 28.65 | 21.02 | 7 | 4618 | 520 | 56286922 |
Red blood cell sedimentation rate abnormal | 27.89 | 21.02 | 18 | 4607 | 18655 | 56268787 |
Clostridium difficile colitis | 25.40 | 21.02 | 17 | 4608 | 18721 | 56268721 |
Dementia | 24.30 | 21.02 | 16 | 4609 | 17142 | 56270300 |
Thrombotic microangiopathy | 21.69 | 21.02 | 12 | 4613 | 9399 | 56278043 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatocellular injury | 85.82 | 26.26 | 43 | 3312 | 21501 | 31672488 |
Spinal muscular atrophy | 78.60 | 26.26 | 16 | 3339 | 395 | 31693594 |
Motor neurone disease | 74.97 | 26.26 | 16 | 3339 | 500 | 31693489 |
Pneumococcal sepsis | 74.78 | 26.26 | 18 | 3337 | 972 | 31693017 |
Stoma closure | 66.66 | 26.26 | 13 | 3342 | 256 | 31693733 |
Ischaemic cerebral infarction | 66.60 | 26.26 | 17 | 3338 | 1170 | 31692819 |
Lymphadenectomy | 62.42 | 26.26 | 13 | 3342 | 360 | 31693629 |
Bronchial disorder | 59.68 | 26.26 | 16 | 3339 | 1333 | 31692656 |
Lower respiratory tract infection bacterial | 59.27 | 26.26 | 13 | 3342 | 463 | 31693526 |
Increased bronchial secretion | 55.17 | 26.26 | 16 | 3339 | 1778 | 31692211 |
Urethral valves | 54.01 | 26.26 | 11 | 3344 | 272 | 31693717 |
Cholestasis | 52.97 | 26.26 | 33 | 3322 | 25042 | 31668947 |
Sputum increased | 52.35 | 26.26 | 16 | 3339 | 2129 | 31691860 |
Disease complication | 49.54 | 26.26 | 16 | 3339 | 2547 | 31691442 |
Scoliosis | 49.32 | 26.26 | 16 | 3339 | 2583 | 31691406 |
Demyelination | 47.31 | 26.26 | 16 | 3339 | 2939 | 31691050 |
Motor dysfunction | 45.25 | 26.26 | 19 | 3336 | 6320 | 31687669 |
Resuscitation | 45.24 | 26.26 | 13 | 3342 | 1398 | 31692591 |
Respiratory tract infection bacterial | 44.75 | 26.26 | 13 | 3342 | 1453 | 31692536 |
Metabolic disorder | 42.67 | 26.26 | 16 | 3339 | 3958 | 31690031 |
Chest X-ray abnormal | 42.29 | 26.26 | 16 | 3339 | 4057 | 31689932 |
Brain injury | 39.97 | 26.26 | 17 | 3338 | 5833 | 31688156 |
Circulatory collapse | 39.21 | 26.26 | 25 | 3330 | 19719 | 31674270 |
Anaphylactic shock | 38.68 | 26.26 | 22 | 3333 | 14123 | 31679866 |
Lung consolidation | 37.71 | 26.26 | 16 | 3339 | 5457 | 31688532 |
Muscle atrophy | 37.13 | 26.26 | 17 | 3338 | 6944 | 31687045 |
Intestinal ischaemia | 36.94 | 26.26 | 17 | 3338 | 7028 | 31686961 |
Anaphylactic reaction | 36.59 | 26.26 | 28 | 3327 | 29525 | 31664464 |
Stevens-Johnson syndrome | 34.50 | 26.26 | 22 | 3333 | 17350 | 31676639 |
Hepatitis cholestatic | 33.62 | 26.26 | 16 | 3339 | 7130 | 31686859 |
Mechanical ventilation | 33.36 | 26.26 | 11 | 3344 | 1868 | 31692121 |
Cerebral ischaemia | 33.21 | 26.26 | 15 | 3340 | 5940 | 31688049 |
Secretion discharge | 32.58 | 26.26 | 14 | 3341 | 4923 | 31689066 |
Kounis syndrome | 32.24 | 26.26 | 11 | 3344 | 2073 | 31691916 |
Meningitis aseptic | 31.97 | 26.26 | 12 | 3343 | 2976 | 31691013 |
Endotracheal intubation | 28.80 | 26.26 | 11 | 3344 | 2859 | 31691130 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic reaction | 89.22 | 19.86 | 67 | 6824 | 74907 | 70846646 |
Hepatocellular injury | 87.61 | 19.86 | 55 | 6836 | 46036 | 70875517 |
Cholestasis | 83.23 | 19.86 | 54 | 6837 | 47818 | 70873735 |
Spinal muscular atrophy | 78.93 | 19.86 | 16 | 6875 | 422 | 70921131 |
Motor neurone disease | 74.10 | 19.86 | 16 | 6875 | 577 | 70920976 |
Acute generalised exanthematous pustulosis | 73.78 | 19.86 | 34 | 6857 | 15363 | 70906190 |
Pneumococcal sepsis | 69.15 | 19.86 | 18 | 6873 | 1458 | 70920095 |
Stoma closure | 67.01 | 19.86 | 13 | 6878 | 272 | 70921281 |
Meningitis aseptic | 53.51 | 19.86 | 21 | 6870 | 6398 | 70915155 |
Lower respiratory tract infection bacterial | 52.46 | 19.86 | 13 | 6878 | 864 | 70920689 |
Bronchial disorder | 52.21 | 19.86 | 16 | 6875 | 2338 | 70919215 |
Ischaemic cerebral infarction | 52.19 | 19.86 | 16 | 6875 | 2341 | 70919212 |
Bone erosion | 50.14 | 19.86 | 26 | 6865 | 15147 | 70906406 |
Lymphadenectomy | 48.80 | 19.86 | 13 | 6878 | 1151 | 70920402 |
Bronchiectasis | 48.69 | 19.86 | 26 | 6865 | 16071 | 70905482 |
Hepatitis cholestatic | 48.59 | 19.86 | 24 | 6867 | 12626 | 70908927 |
Increased bronchial secretion | 47.92 | 19.86 | 16 | 6875 | 3077 | 70918476 |
Nail dystrophy | 46.54 | 19.86 | 12 | 6879 | 936 | 70920617 |
Kounis syndrome | 46.38 | 19.86 | 16 | 6875 | 3395 | 70918158 |
Jaundice | 45.03 | 19.86 | 38 | 6853 | 50070 | 70871483 |
Respiratory tract infection bacterial | 43.66 | 19.86 | 13 | 6878 | 1724 | 70919829 |
Sputum increased | 43.61 | 19.86 | 16 | 6875 | 4056 | 70917497 |
Anaphylactic shock | 43.03 | 19.86 | 31 | 6860 | 32459 | 70889094 |
Stevens-Johnson syndrome | 42.47 | 19.86 | 32 | 6859 | 35875 | 70885678 |
Disease complication | 42.00 | 19.86 | 16 | 6875 | 4501 | 70917052 |
Resuscitation | 39.86 | 19.86 | 13 | 6878 | 2324 | 70919229 |
Axillary pain | 38.20 | 19.86 | 12 | 6879 | 1903 | 70919650 |
Demyelination | 37.88 | 19.86 | 17 | 6874 | 7219 | 70914334 |
Toxic epidermal necrolysis | 37.62 | 19.86 | 31 | 6860 | 39526 | 70882027 |
Brain injury | 37.41 | 19.86 | 19 | 6872 | 10598 | 70910955 |
Drug hypersensitivity | 37.19 | 19.86 | 80 | 6811 | 262379 | 70659174 |
Clostridium difficile colitis | 36.88 | 19.86 | 27 | 6864 | 28969 | 70892584 |
Scoliosis | 36.34 | 19.86 | 16 | 6875 | 6495 | 70915058 |
Metabolic disorder | 36.16 | 19.86 | 17 | 6874 | 8023 | 70913530 |
Chest X-ray abnormal | 34.92 | 19.86 | 16 | 6875 | 7128 | 70914425 |
Pruritus | 34.57 | 19.86 | 92 | 6799 | 345468 | 70576085 |
Drug reaction with eosinophilia and systemic symptoms | 32.80 | 19.86 | 34 | 6857 | 57979 | 70863574 |
Lung consolidation | 32.62 | 19.86 | 16 | 6875 | 8290 | 70913263 |
Intestinal ischaemia | 32.36 | 19.86 | 18 | 6873 | 12046 | 70909507 |
Circulatory collapse | 32.07 | 19.86 | 27 | 6864 | 35447 | 70886106 |
Muscle atrophy | 32.06 | 19.86 | 17 | 6874 | 10353 | 70911200 |
Hypothyroidism | 31.77 | 19.86 | 30 | 6861 | 45725 | 70875828 |
Mechanical ventilation | 30.85 | 19.86 | 11 | 6880 | 2570 | 70918983 |
Tachypnoea | 28.39 | 19.86 | 23 | 6868 | 28615 | 70892938 |
Motor dysfunction | 28.39 | 19.86 | 17 | 6874 | 13053 | 70908500 |
Jaundice cholestatic | 28.24 | 19.86 | 15 | 6876 | 9169 | 70912384 |
Catheter site haemorrhage | 27.38 | 19.86 | 12 | 6879 | 4819 | 70916734 |
Neutropenia | 27.25 | 19.86 | 70 | 6821 | 257086 | 70664467 |
Endotracheal intubation | 25.29 | 19.86 | 11 | 6880 | 4335 | 70917218 |
Mixed liver injury | 24.42 | 19.86 | 12 | 6879 | 6237 | 70915316 |
Bronchospasm | 24.08 | 19.86 | 19 | 6872 | 22773 | 70898780 |
Cerebral ischaemia | 23.81 | 19.86 | 14 | 6877 | 10398 | 70911155 |
Purpura | 23.45 | 19.86 | 17 | 6874 | 17958 | 70903595 |
Liver injury | 23.10 | 19.86 | 24 | 6867 | 41011 | 70880542 |
Aspartate aminotransferase increased | 23.10 | 19.86 | 43 | 6848 | 126935 | 70794618 |
Appendicitis | 22.23 | 19.86 | 16 | 6875 | 16717 | 70904836 |
Secretion discharge | 21.02 | 19.86 | 14 | 6877 | 12919 | 70908634 |
Lung infiltration | 20.66 | 19.86 | 17 | 6874 | 21607 | 70899946 |
Atelectasis | 20.12 | 19.86 | 19 | 6872 | 28943 | 70892610 |
Hepatitis acute | 20.05 | 19.86 | 14 | 6877 | 13948 | 70907605 |
Cholangitis | 19.98 | 19.86 | 13 | 6878 | 11536 | 70910017 |
Injury | 19.97 | 19.86 | 28 | 6863 | 65217 | 70856336 |
None
Source | Code | Description |
---|---|---|
FDA MoA | N0000000202 | beta Lactamase Inhibitors |
FDA EPC | N0000175930 | beta Lactamase Inhibitor |
CHEBI has role | CHEBI:35474 | anti-anxiety agents |
CHEBI has role | CHEBI:35625 | beta-lactamase inhibitors |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:33281 | antibiotics |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D065093 | beta-Lactamase Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Klebsiella cystitis | indication | 60867007 | |
Pneumonia due to Klebsiella pneumoniae | indication | 64479007 | |
Urinary tract infectious disease | indication | 68566005 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Acute bacterial sinusitis | indication | 75498004 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Pneumococcal pneumonia | indication | 233607000 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Bacterial urinary infection | indication | 312124009 | |
Infective otitis media | indication | 312218008 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
Pneumonia due to Staphylococcus aureus | indication | 441658007 | |
Sepsis due to Staphylococcus aureus | indication | 448417001 | |
Sepsis due to Pseudomonas | indication | 448813005 | |
Bacteroides Endometritis | indication | ||
Pneumococcal Acute Otitis Media | indication | ||
Haemophilus Parainfluenzae Pneumonia | indication | ||
Pseudomonas Aeruginosa Urinary Tract Infection | indication | ||
Klebsiella Endometritis | indication | ||
Klebsiella Pneumoniae Peritonitis | indication | ||
Haemophilus Influenzae Acute Otitis Media | indication | ||
Moraxella Catarrhalis Pneumonia | indication | ||
Moraxella Catarrhalis Acute Otitis Media | indication | ||
Staphylococcus Aureus Joint Infection | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
E. Coli Peritonitis | indication | ||
Enterobacter Endometritis | indication | ||
Bacteroides Peritonitis | indication | ||
Serratia Urinary Tract Infection | indication | ||
Citrobacter Urinary Tract Infection | indication | ||
Staphylococcus Endometritis | indication | ||
E. Coli Endometritis | indication | ||
Acute otitis media | off-label use | 3110003 | |
Pyrexia of unknown origin | off-label use | 7520000 | |
Chronic purulent otitis media | off-label use | 38394007 | DOID:14247 |
Cholangitis | off-label use | 82403002 | DOID:9446 |
Human bite - wound | off-label use | 262555007 | |
Chancroid | off-label use | 266143009 | DOID:13778 |
Diverticulitis of gastrointestinal tract | off-label use | 271366000 | |
Dog bite - wound | off-label use | 283734005 | |
Cat bite - wound | off-label use | 283782004 | |
Acute exacerbation of chronic bronchitis | off-label use | 425748003 | |
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis | off-label use | ||
Diabetic Foot Infection | off-label use | ||
Obstruction of bile duct | contraindication | 30144000 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
Species | Use | Relation |
---|---|---|
Dogs | Urinary tract infections caused by Escherichia coli | Indication |
Dogs | Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus | Indication |
Dogs | Skin and soft tissue infections caused by Staphylococcus spp | Indication |
Dogs | Skin and soft tissue infections caused by Streptococcus spp | Indication |
Dogs | Skin and soft tissue infections caused by Escherichia coli | Indication |
Dogs | Skin and soft tissue infections caused by Pasteurella spp | Indication |
Cats | Urinary tract infections caused by Escherichia coli | Indication |
Cats | Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus | Indication |
Cats | Skin and soft tissue infections caused by Staphylococcus spp | Indication |
Cats | Skin and soft tissue infections caused by Streptococcus spp | Indication |
Cats | Skin and soft tissue infections caused by Escherichia coli | Indication |
Cats | Skin and soft tissue infections caused by Pasteurella spp | Indication |
Cats | Periodontal infections due aerobic and anaerobic bacteria | Indication |
Product | Applicant | Ingredients |
---|---|---|
CLAVAMOX CHEWABLE Tablets, CLAVAMOX tablets | Zoetis Inc. | 2 |
Clavamox Drops | Zoetis Inc. | 2 |
Clavacillin | Dechra Veterinary Products LLC | 2 |
Amoxicillin and Clavulanate Potassium for Oral Suspension | Dechra Veterinary Products LLC | 2 |
Amoxicillin and Clavulanate Potassium Tablets | Cronus Pharma Specialities India Private Limited | 2 |
Amoxicillin and Clavulanate Potassium for Oral Suspension | Cronus Pharma Specialities India Private Limited | 2 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.07 | acidic |
pKa2 | 13.53 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-lactamase TEM | Enzyme | INHIBITOR | IC50 | 10.19 | WOMBAT-PK | CHEMBL | |||
Beta-lactamase | Enzyme | IC50 | 7.82 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4 | CHEMBL | |||||
Beta-lactamase SHV-1 | Enzyme | IC50 | 7.55 | CHEMBL | |||||
Beta-lactamase | Enzyme | Kd | 6.40 | CHEMBL | |||||
Beta-lactamase OXA-1 | Enzyme | IC50 | 5.49 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 6.10 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.05 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.15 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.07 | CHEMBL | |||||
Carbapenem-hydrolizing beta-lactamase SFC-1 | Enzyme | IC50 | 4.14 | CHEMBL | |||||
Carbepenem-hydrolyzing beta-lactamase KPC | Enzyme | Ki | 4.96 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.17 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8.05 | CHEMBL | |||||
Beta-lactamase SHV-1 | Enzyme | IC50 | 6.77 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 5.07 | CHEMBL | |||||
Beta-lactamase GES-13 | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 5.76 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7.70 | CHEMBL | |||||
Class D beta-lactamase | Unclassified | IC50 | 5.70 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 8 | CHEMBL | |||||
Beta-lactamase SHV-5 | Enzyme | Ki | 4.60 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 7 | CHEMBL | |||||
Beta-lactamase | Enzyme | MPC | 8.72 | WOMBAT-PK | |||||
Beta-lactamase | Enzyme | IC50 | 7.44 | CHEMBL |
ID | Source |
---|---|
N0000005804 | NUI |
D02370 | KEGG_DRUG |
61177-45-5 | SECONDARY_CAS_RN |
21216 | RXNORM |
4018406 | VANDF |
4019680 | VANDF |
C0055860 | UMLSCUI |
CHEBI:48947 | CHEBI |
J01 | PDB_CHEM_ID |
CHEMBL777 | ChEMBL_ID |
DB00766 | DRUGBANK_ID |
CHEMBL1003 | ChEMBL_ID |
D019818 | MESH_DESCRIPTOR_UI |
5280980 | PUBCHEM_CID |
4948 | INN_ID |
11128 | IUPHAR_LIGAND_ID |
23521W1S24 | UNII |
4463 | MMSL |
d04405 | MMSL |
002808 | NDDF |
002809 | NDDF |
395938000 | SNOMEDCT_US |
395939008 | SNOMEDCT_US |
412318009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2270 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2270 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2272 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2272 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2274 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2274 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2275 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2275 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2277 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2277 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2279 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-2279 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8675 | POWDER, FOR SUSPENSION | 42.90 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8675 | POWDER, FOR SUSPENSION | 42.90 mg | ORAL | ANDA | 26 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9249 | TABLET | 125 mg | ORAL | ANDA | 28 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9853 | SUSPENSION | 42.90 mg | ORAL | ANDA | 32 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9853 | SUSPENSION | 42.90 mg | ORAL | ANDA | 32 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9981 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 30 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9981 | POWDER, FOR SUSPENSION | 28.50 mg | ORAL | ANDA | 30 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9982 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 30 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0143-9982 | POWDER, FOR SUSPENSION | 57 mg | ORAL | ANDA | 30 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1619 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1619 | TABLET, CHEWABLE | 28.50 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1643 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1643 | TABLET, CHEWABLE | 57 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1831 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1831 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1852 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1852 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 27 sections |
Amoxicillin and Clavulanate Potassium | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0781-1874 | TABLET, FILM COATED | 125 mg | ORAL | ANDA | 27 sections |